Ember Therapeutics Inc.
Augmenting brown fat to combat metabolic diseases
This article was originally published in Start Up
Executive Summary
The sole investor in a $34 million Series A financing, Third Rock hopes that Ember Therapeutics can be a pioneer in the relatively new field of using brown fat biology to fight metabolic disease. The start-up also has a program in insulin sensitivity, an approach to treating diabetes that has seen the launch of several drugs in the thiazolidinedione class, most of them compromised by major safety concerns.